(Q39417517)

11 September 2017

0 references

Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials (English)

1 reference

11 September 2017

0 references

M D Ferrari

1

1 reference

11 September 2017

E Loder

series ordinal

2

1 reference

11 September 2017

K A McCarroll

series ordinal

3

1 reference

11 September 2017

C R Lines

series ordinal

4

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

11 September 2017

1 reference

11 September 2017

volume

21

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

129-136

1 reference

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Migraine: a comprehensive review of new treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2001.00169.X

10.1046/J.1468-2982.2001.00169.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference